Point-of-care patient self-monitoring of oral vitamin K antagonist therapy
- First Online:
- 553 Downloads
Successful therapy with vitamin K antagonists requires maintaining a patient in the therapeutic international normalized ratio (INR) range for the particular indication under treatment. Achieving this is dependent on the model of dose management under which the therapy is provided. Most patients in the United States are managed by their individual physician and the time in therapeutic range (TTR) is often low. Patients who have monitored their therapy at home with a point-of-care INR monitor have demonstrated an ability to achieve a high rate of TTR as documented in clinical trials. Recently, similar or even better rates of TTR have been demonstrated in patients performing home monitoring outside of a clinical trial. These findings support the recommendations to implement home monitoring in those who have demonstrated competency in self-management strategies.
KeywordsAnticoagulation Warfarin Point-of-care INR monitoring International normalized ratio Quality of care
- 3.Veeger NJGM, Piersma-Wichers M, Tijssen JGP, Hillege HL, van der Meer J (2005) Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2,300 consecutive patients with venous thromboembolism. Brit J Haematol 128:513–519CrossRefGoogle Scholar
- 5.Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029–2037PubMedCrossRefGoogle Scholar
- 18.DeSantis G, Hogan-Schlientz J, Liska G, Kipp S, Sallee R, Wurster M, Ansell J (2012) Real-world warfarin patients achieve and maintain high time in target range, showing suitability for patient self-testing across all age groups. Amer J Hematol 87(suppl):S149Google Scholar